Nuvalent (NUVL) Research & Development (2020 - 2026)
Nuvalent's (NUVL) quarterly Research & Development came in at $83.6 million in Q1 2026, up 12.35% YoY from $74.4 million in Q1 2025, and up 23.32% on a QoQ basis from $67.8 million in Q4 2025.
Nuvalent (NUVL) Research & Development (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Research & Development data on file, last reported at $83.6 million in Q1 2026.
- Quarterly Research & Development rose 12.35% year-over-year to $83.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $316.2 million (up 24.69% YoY) and the FY2025 annual result came in at $307.0 million, up 40.96% from the prior year.
- Research & Development improved to $83.6 million in Q1 2026, from $67.8 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $83.8 million in Q3 2025 to a low of $12.7 million in Q1 2022.
- A 5-year average of $46.2 million and a median of $38.6 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development soared 131.46% — and 2025, when it decreased 2.34%.
- Tracing NUVL's Research & Development over 5 years: stood at $22.9 million in 2022, then jumped by 55.7% to $35.6 million in 2023, then soared by 95.09% to $69.4 million in 2024, then retreated by 2.34% to $67.8 million in 2025, then gained by 23.32% to $83.6 million in 2026.
- The last three Research & Development figures came in at $83.6 million (Q1 2026), $67.8 million (Q4 2025), and $83.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | 83.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 83.61 Mn |
| Dec 31, 2025 | 67.80 Mn |
| Sep 30, 2025 | 83.84 Mn |
| Jun 30, 2025 | 80.91 Mn |
| Mar 31, 2025 | 74.42 Mn |
| Dec 31, 2024 | 69.42 Mn |
| Sep 30, 2024 | 60.55 Mn |
| Jun 30, 2024 | 49.17 Mn |
| Mar 31, 2024 | 38.63 Mn |
| Dec 31, 2023 | 35.59 Mn |
| Sep 30, 2023 | 29.61 Mn |
| Jun 30, 2023 | 25.92 Mn |
| Mar 31, 2023 | 22.13 Mn |
| Dec 31, 2022 | 22.86 Mn |
| Sep 30, 2022 | 14.63 Mn |
| Jun 30, 2022 | 13.56 Mn |
| Mar 31, 2022 | 12.69 Mn |
| Dec 31, 2021 | 13.19 Mn |
| Sep 30, 2021 | 9.06 Mn |
| Jun 30, 2021 | 7.83 Mn |